Context: Low levels of insulinlike growth factor 1 (IGF-1) in pediatric and adolescent Crohn disease (CD) likely contribute to bone and muscle deficits.
C rohn disease (CD) is a chronic inflammatory condition of the gastrointestinal tract associated with defective innate immune regulation. Children and adolescents with CD have multiple risk factors for poor growth and suboptimal gains in bone and muscle mass, including undernutrition, systemic inflammation, decreased sex hormone levels, glucocorticoid therapy, and abnormalities in the growth hormone (GH)-insulinlike growth factor 1 (IGF-1) axis (1, 2) . Inflammatory cytokines impair multiple components of the GH-IGF-1 axis. For example, inflammation causes reductions in IGF-1 levels through inhibition of GH signal transduction and downregulation of GH receptors in hepatocytes (3, 4) and alters IGF-1 bioavailability through reductions in IGF binding protein 3 (IGFBP-3) levels (5) .
A series of preclinical models have demonstrated that both circulating and locally produced IGF-1 are important for musculoskeletal development, with varied effects on cortical and trabecular bone mineral density (BMD), bone structure, and muscle mass (6) (7) (8) . To our knowledge, no longitudinal studies have examined the associations among changes in IGF-1 levels, bone density and structure, and muscle mass in childhood chronic inflammatory disease.
In animal models of colitis, anti-tumor necrosis factor a (TNF-a) therapy resulted in increased serum levels of IGF-1 and increased linear growth (9) . To our knowledge, studies demonstrating changes in IGF-1 and IGFBP3 levels following initiation of anti-TNF-a therapy in patients with CD are limited to two small series in adults (10, 11) ; musculoskeletal outcomes were not addressed.
We recently established a cohort of children and adolescents enrolled at initiation of anti-TNF-a therapy with infliximab (12) (13) (14) . During the 10-week induction, serum parathyroid hormone (PTH), 1,25(OH) 2 D, sex hormone, and bone biomarker levels increased significantly, in association with decreases in cytokine levels and clinical disease activity. Over the subsequent year, tibia peripheral quantitative computed tomography (pQCT) measures of trabecular volumetric BMD, cortical area, and calf muscle area increased significantly-beyond the gains expected with concurrent linear growth. This ancillary study adds serum IGF-1 and IGFBP-3 levels and is the first report, to our knowledge, of dual-energy x-ray absorptiometry (DXA) measures of bone and lean mass in this cohort. The objectives are to (1) identify risk factors for low IGF-1 levels at the time of initiation of anti-TNF-a therapy and correlates of increases in IGF-1 over the 10-week induction therapy and (2) to examine associations of changes in IGF-1 levels during induction therapy and changes in DXA and pQCT musculoskeletal outcomes over the 12 months following initiation of therapy.
Methods
A total of 90 children and adolescents with CD, ages 5 to 21 years, were enrolled in this prospective cohort study at initiation of infliximab therapy at the Children's Hospital of Philadelphia, as previously described (12) (13) (14) . CD was confirmed by endoscopic, histological, and clinical parameters. The study protocol was approved by the Children's Hospital of Philadelphia Institutional Review Board. Informed consent was obtained from participants aged $18 years and a parent or guardian of participants aged ,18 years. Assent was obtained from participants 7 to 17 years of age. Exclusion criteria included prior anti-TNF-a therapy, cognitive/developmental disorders that affected their ability to complete the study procedures, and medical illness or therapies unrelated to CD that could potentially affect bone metabolism, nutrition, or growth, including kidney disease, seizure disorder, and liver disease. Study visits were completed at the first infliximab infusion (baseline visit) and 10 weeks, 6 months, and 12 months later.
Of the 90 participants ,21 years of age, 75 had sufficient stored serum for the ancillary IGF-1 and IGFBP-3 assays at baseline and 10 weeks. Sixty-three of these completed the 12-month visit with complete DXA data. The analyses of linear growth were limited to the 44 participants assumed to have linear growth potential based on bone age ,17 years in boys and ,14 in girls. The prior reports of longitudinal pQCT data included 74 participants who completed the 12-month visit (13) .
Data collection
Disease characteristics, anthropometry, fracture events, and medications were recorded at each visit. Disease activity was assessed using the Pediatric Crohn's Disease Activity Index (PCDAI), based on symptoms (30%), physical examination (30%), laboratory parameters (20%), and growth (20%), with scores ranging from 0 to 100 (15) . Disease activity was categorized as inactive (1 to 10), mild (11 to 30), and moderate to severe (.30). Participants were provided with glucocorticoid diaries and the entries were reviewed at each visit, with total dose of glucocorticoid calculated as mg/kg prednisone during the interval leading to the 12-month visit. Height was measured using a stadiometer and weight using a digital scale. Tanner stage was ascertained by self-assessment questionnaire (16) . Bone age radiographs were obtained at baseline and read on a clinical basis by a pediatric radiologist who was aware of the participants' age but not Tanner stage (12) .
Laboratory measures at each visit included hematocrit, erythrocyte sedimentation rate (ESR, mm/h), serum C-reactive protein (CRP, mg/L), and albumin (g/dL) concentrations, using standard methods in the clinical laboratory. Serum intact PTH concentrations were measured by Quest Diagnostics (San Juan Capistrano, CA) using a chemiluminescence assay (12) .
Serum cytokines, sex hormones, and growth factors were measured at enrollment, 10 weeks, and 12 months. Serum TNFa and interleukin 6 were measured by the Luminex platform and the human cytokine six-plex high-sensitivity antibody bead kit (Millipore, Billerica, MA) (12) . Testosterone and estradiol were tested at Quest Diagnostics (Madison, NJ) using ultrasensitive liquid chromatography-tandem mass spectrometry (14) . Serum IGF-1 levels were measured by enzyme-linked immunosorbent assay (Immunodiagnostics Systems, Tyne & Wear, UK) with an intra-assay coefficient of variation (CV) of 4.6% to 7.2% and inter-assay CV of 4.3% to 6.5%. Serum IGFBP-3 levels were assessed by enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN) with an intra-assay CV of 2.3% to 5.0% and interassay CV of 5.4% to 8.0%.
DXA and pQCT
DXA and pQCT scans were obtained at baseline and 12 months. DXA scans were performed using a Delphi/Discovery (Hologic, Bedford, MA) densitometer. Whole-body, posteroanterior lumbar spine (L1 to L4), and left proximal femur scans were obtained using standard positioning techniques. The DXA outcomes are whole-body bone mineral content (BMC, excluding head) and spine, total hip, and femoral neck areal BMD. To characterize skeletal muscle, we limited whole-body lean mass results to leg lean mass, as previously described (17, 18) , and consistent with the convention in adults to define sarcopenia based on DXA lean mass in the limbs (19) . The DXA instrument was calibrated using a hydroxyapatite spine phantom daily and a whole-body phantom three times per week. The in vitro CV was ,0.6%, and the in vivo CV was ,1%.
Left tibia pQCT scans were obtained using a Stratec XCT2000 device (Orthometrix, White Plains, NY) with a voxel size of 0.4 mm and slice thickness of 2.3 mm, as described (13, 20 ) was assessed at the 66% site. Our CV in children and adolescents was ,2% for all pQCT outcomes.
Analysis plan
Anthropometry, DXA, and pQCT measures and IGF-1 and sex hormone levels were expressed as z scores. Age-and sexspecific height and body mass index (BMI) z scores were generated using national data (12) . Growth velocity z scores were generated from reference curves from .2000 healthy children and adolescents in the Bone Mineral Density in Childhood Study (BMDCS) (21) . Serum IGF-1 levels were converted to sex-specific z scores relative to age (and, for a sensitivity analysis, relative to bone age) based on the mean and standard deviation (SD) of reference values provided by the manufacturer. Testosterone and estradiol values were converted to z scores based on the mean and SD of reference values from Quest Diagnostics (13, 14) . For IGF-1 and sex hormone z score formulation, in cases where the lower limit of two SDs below the mean dropped below 0, the z score was calculated as z score = [LOG10(measured value) 2 LOG10 (reference mean)]/(reference SD/reference mean) (22) .
DXA measures of spine, femoral neck, and total hip areal BMD and whole-body (less head) BMC were converted to sexand race-specific z scores using the reference curves based on data in .2000 healthy children and adolescents in the BMDCS (21) . The BMC and BMD z scores were subsequently adjusted for age, height z score, and the interaction between height z score and age to eliminate the confounding effect of short stature (23) . Sex-and race-specific leg lean mass z scores were also generated using BMDCS data, adjusted for age and leg length z score (Babette Zemel, personal communication). Briefly, the lean mass outcomes from the BMDCS were converted to raceand sex-specific z scores relative to age based on the reference participants using the lambda-mu-sigma method (Chartmaker Program v2.3; The Institute of Child Health, London, United Kingdom) that accounts for the nonlinearity, heteroscedasticity, and skew of bone and body composition data (13) . Similarly, tibia pQCT outcomes were converted to sex-and race-specific z scores using our reference curves generated in .600 concurrent healthy participants, as previously described (13, 20, 24) . The pQCT cortical and trabecular volumetric BMD outcomes were assessed relative to age. The tibia cortical geometry and calf muscle area z scores were assessed relative to age and adjusted for tibia length z score (13, 23, 25) .
All analyses were performed using SAS 9.4. Because many laboratory and musculoskeletal outcomes were normally distributed at some time points but not others, we provided mean and SD and median and interquartile range for all variables. We used paired t tests to assess for differences in normally distributed variables over time and Wilcoxon rank sum for nonnormally distributed variables. In assessing changes in levels of cytokines, CRP, and ESR, we used natural log transformed to achieve normality. In comparing z scores to the reference populations, we used single-sample t tests to determine whether values were different from zero.
In assessing for variables associated with IGF-1 z scores over time, accounting for intraparticipant variation, we used mixed models via "proc mixed" in SAS, which takes into account random effects in repeated measures in an individual over time (26) . Hypothesized covariates included BMI z scores, PCDAI score, cytokine levels, sex hormone z scores, and PTH levels, based on reports that PTH increased IGF-1 expression in osteoblasts (27) and PTH infusion increased systemic levels of IGF-1 (28) .
In regression models of changes in bone and muscle z scores, we analyzed whether sex and race contributed to models, and when not, these were omitted from the model. The analyses of linear growth were limited to the 44 participants assumed to have linear growth potential based on bone age ,17 years in boys and ,14 years in girls. Linear regression analyses of the relationship between changes in IGF-1 z score and changes in bone and muscle z scores determined if short-term changes in IGF-1 z scores over the 10-week induction interval were associated with 12-month changes in the DXA and pQCT z scores, adjusted for baseline IGF-1 and DXA or pQCT results. Because changes in bone outcomes may be mediated by changes in muscle mass (29) , we further tested these associations following inclusion of change in measures of muscle in the model (either leg lean mass z score for DXA measures or calf muscle area z score for pQCT measures). We further assessed for whether glucocorticoid use modified any effect between IGF-1 and bone changes. Statistical significance for all analyses was considered for P , 0.05.
Results
A total of 75 participants were eligible for this study, and 63 (84%) completed the 12-month visit. The baseline participant and disease characteristics are shown in Table 1 and are notable for z scores for height (20.48 6 1.02) and BMI (20.17 6 1.09) that are significantly lower (both P , 0.001) than the values reported in the BMDCS reference participants (0.27 6 0.80 and 0.46 6 0.82), respectively (30) . Thirty-three participants (44%) were treated with glucocorticoids during the 12 months, nine of whom were started after the first visit. The baseline demographics, PCDAI score, and height and BMI z scores did not differ in the 63 who did complete the 12-month visit compared with the 12 who did not.
Clinical course and IGF-1 levels Table 2 summarizes clinical disease activity, inflammatory markers, and laboratory studies of IGF-1 and IGFBP-3 at each visit among the 63 who completed the 12-month visit. As previously reported, disease severity improved markedly between baseline and both 10-week and 12-month follow-up (Fig. 1A) , with concurrent decreases in inflammatory cytokines and other markers of inflammation (13) .
At baseline, IGF-1 levels were significantly low for sex and age (P , 0.001), with a median z score of 21.00. IGF-1 z scores increased significantly between baseline and 10 weeks. IGF-1 z scores were not significantly greater at 12 months compared with baseline (Fig. 1B) , although absolute levels were higher. At each time point, IGF-1 z scores did not differ by sex (data not shown). IGF-BP3 levels increased over 10 weeks but were not significantly different at 12 months.
Among participants with growth potential based on bone age (bone age ,17 years for boys and ,14 years for girls), height velocity z score was significantly greater than referent children and adolescents from the BMDCS (21), with a median (interquartile range) of 1.15 (0.37 to 1.68). In this group of participants with growth potential, neither baseline levels of IGF-1 z score nor the change in IGF-1 z score over the 10-week induction were associated with height velocity z score over the 12 months (b estimate, 0.001 6 0.111, P = 0.99, and 0.05 6 0.28, P = 0.85, respectively). Similarly, among prepubertal participants, height velocity z scores from baseline to 12 months were not associated with IGF-1 z scores at any time point (all P . 0.05).
At baseline, IGF-1 z score was positively associated with BMI z score and PTH level and negatively associated with PCDAI, CRP, and ESR (all P , 0.05 in univariate analyses). The change in IGF-1 z score over 10 weeks was positively associated with the change in PTH level and negatively associated with the change in TNF-a level over the same time period (P , 0.01).
In separate mixed-model regression assessing data from all three time points and accounting for intrasubject variation (Table 3) , all factors except testosterone z score were either positively (in the case of BMI z score, PTH, and estradiol z score in females) or negatively (in the case of PCDAI and inflammatory factors) and significantly associated with IGF-1 z score.
DXA and pQCT results
We next set out to examine associations between short-term changes in IGF-1 z score during induction and changes in musculoskeletal outcomes over the 12 months following initiation of anti-TNF-a therapy. The DXA results have not previously been reported and are summarized in Table 4 and Supplemental Fig. 1 . At baseline, participants had low whole-body BMC (P , 0.001); low total hip (P , 0.0001), femoral neck (P , 0.0001), and spine (P , 0.0001) areal BMD; and low leg lean mass (P , 0.0001) z scores compared with the BMDCS cohort. With the exception of spine areal BMD, each of these z score measures improved significantly over 12 months. At 12 months, z scores for spine and femoral neck BMD (both P , 0.001) and leg lean mass (P , 0.05) remained low compared with the reference cohort.
In this analytic subset of 63 participants, as reported previously for the larger cohort of 74 participants (13) , pQCT measures of trabecular volumetric BMD, cortical area, cortical thickness, periosteal circumference, and calf muscle area z scores were significantly low at baseline a Data are presented as n (%) or mean 6 SD and median (range).
b Bone age films available in 61 participants at baseline.
doi: 10.1210/jc.2017-01916 https://academic.oup.com/jcemcompared with concurrent local controls (i.e., the .650 healthy children and adolescents whose pQCT measures were used to generate the age-, sex-, and race-specific curves that were further adjusted for bone length (20)). Trabecular volumetric BMD, cortical area, cortical thickness, and calf muscle area improved significantly relative to these referent individuals. Cortical BMD and endosteal circumference z scores decreased, although the decrease in endosteal circumference z score observed in the larger cohort did not achieve statistical significance in this subset (P = 0.07). 
(2612-3239)
The baseline and 10-week results are limited to the 63 participates with 12-month data.
Abbreviations: IL-6, interleukin 6; IQR, interquartile range. a P , 0.001 compared with baseline.
b The significance for differences between baseline and follow-up levels of cytokine, CRP, and ESR levels is based on natural log-transformed values.
c P . 0.05 compared with 10 weeks.
d P , 0.01 compared with 10 weeks.
e P , 0.05 compared with baseline.
f P , 0.0001 for single-sample t test assessing for z score being different from 0. Associations among changes in IGF-1 and musculoskeletal outcomes Table 5 summarizes the linear regression analyses of changes in IGF-1 z score over the 10-week induction period as a predictor of the 12-month changes in DXA and pQCT z scores, adjusted for baseline values. The short-term change in IGF-1 z score was positively associated with 12-month changes in all DXA and pQCT z scores with the exception of spine areal BMD, tibia cortical volumetric BMD, and periosteal circumference z score. For example, a unit greater increase in IGF-1 z score over the 10-week induction was associated with a 0.25 greater increase in whole-body BMC z score over 12 months. Results did not differ when assessed using IGF-1 z scores formulated by bone age instead of chronological age (data not shown). Cumulative glucocorticoid exposure in mg/kg during the study was inversely associated with 12-month changes in whole-body BMD (P , 0.01) and spine BMD (P , 0.05), femoral neck areal BMD (P , 0.0001), and total hip BMD (P , 0.01); however, these inverse associations did not attenuate the b coefficient in the relationship between IGF-1 and changes in these measures.
Improvements in bone outcomes may be mediated by gains in muscle (29) . Table 5 demonstrates that adjustment for increases in muscle mass (DXA) or muscle area (pQCT) attenuated the associations between increases in IGF-1 z scores and bone z scores. In the adjusted model, only change in whole-body BMC z score was significantly associated with change in IGF-1 z score, independent of gains in muscle z scores. All analyses are univariate. The mixed model takes into account variables at baseline, 10 weeks, and 1 year. Boldface represents statistical significance at P , 0.05.
Abbreviations: CI, confidence interval; IL-6, interleukin 6. a Natural log value used to achieve normality. 
Discussion
This study is novel in many ways. To our knowledge, it is the first to evaluate changes in IGF-1 levels following anti-TNF-a therapy in children and adolescents and the first in any inflammatory disease state to demonstrate the association of changes in IGF-1 with improvements in musculoskeletal outcomes. We demonstrated dramatic gains in DXA measures of whole-body BMC, as an overall index of bone accrual, total hip, and femoral neck areal BMD and leg lean mass-above and beyond gains due to concurrent linear growth (as our z scores were adjusted for age and height/leg length z score at each time point). These data suggest that the adverse effects of inflammation on GH metabolism contribute to the musculoskeletal deficits in CD. This is also the first study, to our knowledge, to report changes in DXA measures of bone and lean mass in children with any chronic disease following anti-TNF-a treatment. The parallel assessment of pQCT volumetric BMD and cortical structure provides insights into the relationship of changes in IGF-1 with discrete components of bone mass that cannot be discerned using DXA two-dimensional measures of areal BMD. The pQCT findings suggest that the gains in DXA total hip and femoral neck areal BMD likely reflect gains in trabecular volumetric BMD and cortical thickness, and the gains in whole-body BMC also likely reflect gains in cortical thickness rather than density. Of note, the failure to detect improvements in spine areal BMD during infliximab therapy or an association between gains in IGF-1 levels and spine areal BMD may reflect the limitations of spine DXA, where the predominantly trabecular vertebral body is superimposed by large quantities of cortical bone in the posterior spinous processes (31) . We have previously demonstrated that DXA areal BMD on the posteroanterior projection is less sensitive to disease and treatment effects compared with lateral DXA or spine QCT (32, 33) . Although this study is limited by lack of DXA and QCT scans at the same anatomic site, these data suggest that the proximal femur scan may provide more insight compared with the spine in DXA studies. This is noteworthy because the most recent International Society for Clinical Densitometry Pediatric Position Development Conference concluded that the whole body and spine are the preferred DXA scan sites in children, given concerns that the proximal femur is less reliable due to variability in skeletal development and regions of interest (34) . Our findings, combined with the availability of robust normative data for proximal femur DXA in children aged $5 years, suggest a role for measurement of the proximal femur in clinical practice and future research.
The positive correlations between change in IGF-1 and bone accrual were attenuated when adjusted for concurrent gains in muscle. This is consistent with the functional muscle bone unit paradigm that postulates developmental changes in bone strength are secondary to the increasing loads imposed by larger muscle forces (35) . A recent cross-sectional study among healthy girls in early puberty demonstrated that the relationships between IGF-1 levels and BMC/height were mediated by lean mass (29) . Our observational study is unable to distinguish between direct IGF-1 effects on bone, changes mediated by IGF-1-induced gains in muscle forces, or the impact of lesser inflammation and better nutrition on IGF-1 metabolism and bone and muscle accrual. Although low IGF-1 levels have been described in CD (36, 37) , this is the first study, to our knowledge, to examine correlates of IGF-1 levels and changes during anti-TNF-a therapy in children. Our comprehensive assessment demonstrated associations with BMI as a measure of nutrition status, multiple markers of systemic inflammation, and sex hormones. Systemic inflammation has been implicated in the suppression of the GH-mediated production of IGF-1 in both preclinical studies (9, 38) and studies of infectious disease (39) , apparently via downregulation of GH receptors and impaired GH signaling in the presence of inflammation (9) . To our knowledge, this is also the first study to reveal increased IGFBP-3 in children and adolescents following initiation of anti-TNF-a treatment, as was seen among adults (11) . Whereas it is well established that IGF-1 expression is decreased in the setting of both malnutrition and inflammation, IGFBP-3 is considered more sensitive to the adverse effects of inflammation (36) . We saw a rise in IGFBP-3 in the 10 weeks following initiation of anti-TNF-a treatment but a decrease in IGFBP-3 levels toward baseline by 12 months. Although the cause of this is not certain, we documented increases in TNF-a again by the 12-month point, potentially indicating that a subset of patients had a dampening in their response to therapy.
We also demonstrated that IGF-1 was positively associated with estradiol levels. Estradiol potentiates the release of GH-the predominant driver of IGF-1 production-providing a potential mechanism for this relationship (40) . We had previously noted increases in both testosterone and estradiol following antiinflammatory treatment (14) . Although testosterone is converted to estradiol peripherally, contributing to the GH surge (40), we did not see a link between testosterone and IGF-1 z scores in this modestly sized cohort with substantial heterogeneity in pubertal maturation. Similarly, we did not see links between IGF-1 z scores and height velocity, potentially emphasizing the complex relationship between growth factors, disease severity, and linear growth.
We previously reported increases in PTH in this cohort following induction with infliximab that were attributed to known effects of cytokines to downregulate PTH expression (12) . Because of prior reports linking PTH infusion to increases in IGF-1 (28), we evaluated PTH levels as a predictor of IGF-1 z scores, finding positive associations over time. Nevertheless, the cause-and-effect nature of this relationship requires assessment in subsequent cohorts. We previously demonstrated higher levels of PTH during pubertal growth in healthy children (41) , and the potential exists in the current study that higher levels of IGF-1 led to rapid bone accrual (due to accelerated linear growth and increases in bone density and dimensions), leading to increased calcium demands and a compensatory increase in PTH.
This study has important limitations. First and foremost, the observational study design prohibits any conclusions regarding causation, either with regard to the direct impact of TNF-a therapy on IGF-1 levels or the direct impact of IGF-1 on musculoskeletal outcomes. Changes in dietary intake, intestinal absorption, physical activity, and cessation of glucocorticoid therapy may have contributed to the changes observed here. As noted in our prior publications in this cohort, anti-TNF-a medications are the standard of care for children and adolescents with moderate to severe CD. Therefore, it was not possible to enroll patients with CD with comparable disease severity who were not treated with anti-TNF-a as untreated controls. Second, we did not have bone biopsy specimens or paired DXA and QCT scans at the same skeletal site. Third, IGF-1 z scores were formulated based on sex and age instead of on pubertal status due to a lack of normal ranges by pubertal stages of the assay used. Also, we were unable to express the IGFBP-3 results as z scores due to lack of available reference values for the assay used. However, the 12-month change in IGFBP-3 would be expected to be small. We relied on a validated survey of child self-assessment of puberty instead of investigator examination, potentially leading to misclassification of pubertal stage. Finally, we measured total levels of IGF-1, whereas it is the unbound portion of IGF-1 that is bioavailable and produces effects at the tissue level (42) . These limitations are outweighed by the many strengths. To our knowledge, this is the first study to report changes in clinically available DXA outcomes following anti-TNF-a therapy in children and adolescents and the first to assess concurrent changes in IGF-1 levels.
In conclusion, we documented strong associations between greater disease severity and inflammation and lower IGF-1 z scores, suggesting initial suppression and later recovery of IGF-1 following anti-TNF-a treatment. Changes in IGF-1 were associated with improvements in a spectrum of musculoskeletal outcomes. Future studies are needed to determine the effects on physical function and fracture risk. These data may provide guidance for expected changes in growth factors and DXA outcomes following anti-TNF-a treatment in pediatric and adolescent patients with CD.
